Indicated for: type 2 diabetes; obesity
Substance: liraglutide (GLP-1 receptor agonist)
ATC: A10BJ02 (Alimentary tract and metabolism | Blood glucose lowering drugs, excl. insulins | Glucagon-like peptide-1 (GLP-1) analogues)
Liraglutide is a medication used for the treatment of type 2 diabetes and obesity. It is a glucagon-like peptide-1 (GLP-1) analog that works by stimulating insulin secretion, reducing glucagon secretion, and slowing gastric emptying, thereby lowering blood sugar levels and reducing appetite.
Liraglutide is administered as a subcutaneous injection, usually once daily, and is used either for blood sugar control in patients with type 2 diabetes or for weight loss in patients with obesity or overweight associated with other conditions (such as hypertension or dyslipidemia).
Side effects may include nausea, vomiting, diarrhea, constipation, abdominal pain, or, in rare cases, pancreatitis. It may also cause appetite suppression and weight loss. It is important to use the medication as prescribed by a doctor, and patients should be monitored to prevent complications.